TCGA-P3-A5QE-01A-11R-A28V-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.430
- G2M_CHECKPOINT+0.300
- MITOTIC_SPINDLE+0.260
- INTERFERON_ALPHA_RESPONSE+0.240
- ALLOGRAFT_REJECTION+0.180
- INTERFERON_GAMMA_RESPONSE+0.130
- PANCREAS_BETA_CELLS+0.070
- SPERMATOGENESIS+0.050
- DNA_REPAIR+0.010
- KRAS_SIGNALING_DN+0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ANGIOGENESIS-0.540
- MYC_TARGETS_V2-0.460
- MYOGENESIS-0.450
- OXIDATIVE_PHOSPHORYLATION-0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- MTORC1_SIGNALING-0.400
- COAGULATION-0.380
- GLYCOLYSIS-0.360
- APICAL_JUNCTION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899995 | — | — | 0.876 |
| 2 | TCGA-QK-A6V9-01A-11R-A34R-07 | — | — | 0.871 |
| 3 | ERR2208907 | — | — | 0.870 |
| 4 | AUR-AF9A-TTP1-A-1-0-R-A741-41 | — | D | 0.853 |
| 5 | TCGA-DQ-7591-01A-11R-2081-07 | — | — | 0.849 |
| 6 | TCGA-85-A4PA-01A-11R-A24Z-07 | — | cohortMD2 | 0.841 |
| 7 | 5b217223-8b43-47b6-a694-c808b643c3c3 | — | — | 0.839 |
| 8 | TCGA-QK-A6IF-01A-11R-A31N-07 | — | — | 0.821 |
| 9 | SRR4195665 | — | — | 0.817 |
| 10 | NALM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |